866-997-4948(US-Canada Toll Free)

Global Retinal Drugs Market 2017-2021

Published By :

Technavio

Published Date : Jul 2017

Category :

Infectious Disease

No. of Pages : 88 Pages

About Retinal Drugs
Ophthalmic disorders largely consist of minor disorders that need minimal or no treatment, however, few other disorders become critical in nature and need specialist care. A delay in treatment in case of critical disorders may even lead to vision loss.
Retinal disorders, glaucoma, dry-eye, infection/inflammation in the eyes, and allergic/otic problems are the major ophthalmic disorders. The retinal drugs market holds the largest share of the global ophthalmic disorder treatment market, followed by glaucoma treatment drugs market. The global retinal drugs market is expected to grow with a high CAGR of 11.66% due to the high demand of age-related macular degeneration (AMD) drugs and diabetic eye disease drugs. This is due to the rising geriatric population and an increase in the population with diabetes. Also, countries across the globe are investing significantly in the healthcare sector. This has, in turn, increased awareness and diagnosis rate of the disease.

Technavios analysts forecast the global retinal drugs market to grow at a CAGR of 11.66% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs in retinal disorders market.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Retinal Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron
Other prominent vendors
Merck
Shire
Teva Pharmaceutical
ThromboGenics
Market driver
Rising geriatric population and corresponding increase in patient pool
For a full, detailed list, view our report

Market challenge
Shortage of trained professionals
For a full, detailed list, view our report

Market trend
Rising use of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Market landscape
Market overview
Five forces analysis
PART 06: Pipeline landscape
PART 07: Segmentation by type of disease
Global MD drugs market
Global diabetic eye disease drugs market
Global other retinal drugs market
PART 08: Market segmentation by ROA
IV
Intravitreal
PART 09: Geographical segmentation
Retinal drugs market in Americas
Retinal drugs market in EMEA
Retinal drugs market in APAC
Decision framework
PART 10: Drivers and challenges
Market drivers
Market challenges
PART 11: Market trends
PART 12: Vendor landscape
Competitive scenario
Bayer
Novartis
Regeneron
F. Hoffmann-La Roche
Other prominent vendors
PART 13: Appendix
List of abbreviations

List of Exhibits
Exhibit 01: Market overview of global ophthalmic drugs market
Exhibit 02: Value chain analysis for global ophthalmic drugs market
Exhibit 03: Types of AMD
Exhibit 04: Stages of AMD
Exhibit 05: Symptoms associated with AMD
Exhibit 06: Diagnosis and management
Exhibit 07: Diabetic eye diseases affecting retina
Exhibit 08: Diagnosis and management of diabetic eye diseases
Exhibit 09: Global retinal drugs market: Snapshot
Exhibit 10: Global retinal drugs market 2016-2021 ($ millions)
Exhibit 11: Opportunity analysis of global retinal drugs market
Exhibit 12: Five forces analysis
Exhibit 13: Pipeline landscape of vendors
Exhibit 14: Key clinical trials
Exhibit 15: Global retinal drugs market by type of disease
Exhibit 16: Global retinal drugs market share by type of disease 2016 and 2021
Exhibit 17: Global MD drugs market 2016-2021 ($ millions)
Exhibit 18: Global MD drugs market: Snapshot
Exhibit 19: Major approved drugs for MD
Exhibit 20: Global MD drugs market by type of AMD 2016
Exhibit 21: Global diabetic eye disease drugs market 2016-2021 ($ millions)
Exhibit 22: Global diabetic eye disease drugs market: Snapshot
Exhibit 23: Major types of diabetic eye diseases affecting retina
Exhibit 24: Diabetic retinopathy: Disease overview
Exhibit 25: Global other retinal drugs market 2016-2021 ($ millions)
Exhibit 26: Global retinal drugs market by ROA 2016
Exhibit 27: Global retinal drugs market by geography 2016 and 2021
Exhibit 28: Global retinal drugs market by geography 2016-2021 ($ millions)
Exhibit 29: Market scenario in Americas
Exhibit 30: Retinal drugs market in Americas 2016-2021 ($ millions)
Exhibit 31: Estimated vision problems in US 2020
Exhibit 32: Market scenario EMEA
Exhibit 33: Retinal drugs market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario APAC
Exhibit 35: Retinal drugs market in APAC 2016-2021 ($ millions)
Exhibit 36: Asian countries with highest diabetic populations
Exhibit 37: Population in age group 60 and above by region 2015 and 2050
Exhibit 38: Major complications associated with diabetes
Exhibit 39: New cases of diabetes 2040
Exhibit 40: Biosimilars in ophthalmic drugs market
Exhibit 41: Competitive structure analysis of global retinal drugs market 2016
Exhibit 42: Strategic success factors of companies in global retinal drugs market
Exhibit 43: Bayer: Key highlights
Exhibit 44: Bayer: Strength assessment
Exhibit 45: Bayer: Strategy assessment
Exhibit 46: Bayer: Opportunity assessment
Exhibit 47: Novartis: Key highlights
Exhibit 48: Novartis: Strength assessment
Exhibit 49: Novartis: Strategy assessment
Exhibit 50: Novartis: Opportunity assessment
Exhibit 51: Regeneron: Key highlights
Exhibit 52: Regeneron: Strength assessment
Exhibit 53: Regeneron: Strategy assessment
Exhibit 54: Regeneron: Opportunity assessment
Exhibit 55: F. Hoffmann-La Roche: Key highlights
Exhibit 56: F. Hoffmann-La Roche: Strength assessment
Exhibit 57: F. Hoffmann-La Roche: Strategy assessment
Exhibit 58: F. Hoffmann-La Roche: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *